Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Net Cash Flow (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Net Cash Flow for 4 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 86.14% to -$5.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$167.3 million, a 98.85% decrease, with the full-year FY2025 number at -$167.3 million, down 98.85% from a year prior.
  • Net Cash Flow was -$5.2 million for Q4 2025 at Phathom Pharmaceuticals, up from -$14.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $167.7 million in Q4 2023 to a low of -$84.9 million in Q1 2025.
  • A 4-year average of -$9.1 million and a median of -$29.5 million in 2022 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 556.3% in 2023; the steepest drop was 211.16% in 2023.
  • Phathom Pharmaceuticals' Net Cash Flow stood at -$41.5 million in 2022, then surged by 504.61% to $167.7 million in 2023, then crashed by 122.31% to -$37.4 million in 2024, then skyrocketed by 86.14% to -$5.2 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Net Cash Flow are -$5.2 million (Q4 2025), -$14.4 million (Q3 2025), and -$62.7 million (Q2 2025).